Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation

Tie, J; Gibbs, P; Lipton, L; Christie, M; Jorissen, RN; Burgess, AW; Croxford, M; Jones, I; Langland, R; Kosmider, S; McKay, D; Bollag, G; Nolop, K; Sieber, OM; Desai, J

Author(s): Tie, J; Gibbs, P; Lipton, L; Christie, M; Jorissen, RN; Burgess, AW; Croxford, M; Jones, I; Langland, R; Kosmider, S; McKay, D; Bollag, G; Nolop, K; Sieber, OM; Desai, J;
Details: Publication Year 2011-05-01,Volume 128,Issue #9,Page 2075-84
Journal Title: Int J Cancer
Publication Type: Journal Article
Abstract: BRAF(V600E) mutations are found in 10% of colorectal cancers (CRCs). The low frequency of this mutation therefore makes it a challenging target for drug development, unless subsets of patients with higher rates of BRAF(V600E) can be defined. Knowledge of the concordance between primary-metastasis pairs and the impact of BRAF(V600E) on outcome would also assist in optimal drug development. We selected primary CRCs from 525 patients (stages I-IV) evenly matched for age (<70 and >/=70), gender and tumor location (right, left and rectum), and 81 primary-metastasis pairs. BRAF(V600E), KRAS mutation and microsatellite instability (MSI) were determined and correlated with clinical features and patient outcomes. In multivariate analyses, increasing patient age (p = 0.04), female gender (p = 0.0005) and right-sided tumor location (p < 0.0001) were independently associated with BRAF(V600E). The prevalence of BRAF(V600E) was considerably higher in older (age > 70) females with KRAS wild-type right-sided colon cancers (50%) compared to the unselected cohort (10%). BRAF(V600E) was associated with inferior overall survival in metastatic CRC (HR = 2.02; 95% CI 1.26-3.26), particularly evident in patients treated with chemotherapy, and is independent of MSI status. BRAF status was concordant in all primary tumors and matched metastases (79 wild-type pairs and two mutant pairs). Clinicopathological and molecular features can identify CRC patients with a higher prevalence of BRAF(V600E). Patients with BRAF(V600E) wild-type primary tumor do not appear to acquire the mutation in their metastases, and BRAF(V600E) is associated with poorer outcomes in metastatic patients. Our findings are timely and will help inform the rational development of BRAF(V600E) inhibitors in CRC.
Publisher: Wiley
Publisher's Version: https://doi.org/10.1002/ijc.25555
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2014-05-14 03:05:54